The FDA has approved an adjuvant combination of pembrolizumab and belzutifan for adults with high-risk clear cell renal cell carcinoma following surgery, according to a Dana-Farber-backed report. The regimen pairs an immune checkpoint inhibitor with a hypoxia-inducible factor-2α (HIF-2α) inhibitor to target tumor biology post-resection. The approval highlights continued emphasis on escalation strategies in the adjuvant setting—where durable disease control is the goal—using molecularly driven add-ons rather than immunotherapy alone. For sponsors, the decision also reinforces the commercial relevance of combining pathway-based targets with immuno-oncology in earlier-line disease. Clinically, the label focuses on high-risk patients after nephrectomy or partial nephrectomy, with the primary intent of reducing recurrence risk. The FDA’s action means a new standard-of-care option is now available for oncologists managing post-surgical risk in clear cell RCC.